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Abstract
Objective To evaluate how selection of patients for high sensitivity
cardiac troponin testing affects the diagnosis of myocardial infarction
across different healthcare settings.
Design Prospective study of three independent consecutive patient
populations presenting to emergency departments.
Setting Secondary and tertiary care hospitals in the United Kingdom
and United States.
Participants High sensitivity cardiac troponin I concentrations were
measured in 8500 consecutive patients presenting to emergency
departments: unselected patients in the UK (n=1054) and two selected
populations of patients in whom troponin testing was requested by the
attending clinician in the UK (n=5815) and the US (n=1631). The final
diagnosis of type 1 or type 2 myocardial infarction or myocardial injury
was independently adjudicated.
Main outcome measures Positive predictive value of an elevated
cardiac troponin concentration for a diagnosis of type 1 myocardial
infarction.
Results Cardiac troponin concentrations were elevated in 13.7%
(144/1054) of unselected patients, with a prevalence of 1.6% (17/1054)
for type 1 myocardial infarction and a positive predictive value of 11.8%
(95% confidence interval 7.0% to 18.2%). In selected patients, in whom
troponin testing was guided by the attending clinician, the prevalence
and positive predictive value were 14.5% (843/5815) and 59.7% (57.0%
to 62.2%) in the UK and 4.2% (68/1631) and 16.4% (13.0% to 20.3%)
in the US. Across both selected patient populations, the positive
predictive value was highest in patients with chest pain, with ischaemia
on the electrocardiogram, and with a history of ischaemic heart disease.
Conclusions When high sensitivity cardiac troponin testing is performed
widely or without previous clinical assessment, elevated troponin
concentrations are common and predominantly reflect myocardial injury
rather than myocardial infarction. These observations highlight how
selection of patients for cardiac troponin testing varies across healthcare
settings and markedly influences the positive predictive value for a
diagnosis of myocardial infarction.
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Introduction
Cardiac troponin is integral to the diagnosis of myocardial
infarction,1 but troponin concentrations are often elevated in
patients who do not have acute coronary syndrome. The
universal definition now classifies myocardial infarction as
spontaneous or type 1, due to plaque rupture and coronary
thrombosis, and secondary or type 2 due to myocardial oxygen
supply-demand imbalance.2-5 Patients with elevated cardiac
troponin concentrations in the absence of myocardial ischaemia
are classified as having myocardial injury.6 Although patients
with type 2 myocardial infarction or myocardial injury are
increasingly recognised in clinical practice,2-10 they represent a
heterogeneous group with overt or covert major illness for whom
no evidence base exists to guide optimal cardiac investigation
or treatment.
We have shown that lowering the diagnostic threshold by using
a more sensitive cardiac troponin assay reduced recurrent
myocardial infarction or death in patients redefined as having
type 1 myocardial infarction.11 However, use of these lower
diagnostic thresholds more than doubled the number of patients
with type 2 myocardial infarction or myocardial injury with no
improvement in their outcome despite undergoing additional
cardiac investigation.2 The introduction of high sensitivity
cardiac troponin assays may further increase the frequency of
type 2 myocardial infarction or myocardial injury,6 7 potentially
leading to diagnostic uncertainty and unnecessary investigation
of patients without acute coronary syndrome.12-14
Patients attending the emergency department often have
simultaneous testing for both cardiac and non-cardiac
conditions,15 to facilitate early diagnosis or discharge. In this
context, a non-selective approach to high sensitivity cardiac
troponin testing may contribute to diagnostic uncertainty.16 Our
aim was to evaluate how selection of patients for high sensitivity
cardiac troponin testing affects the diagnosis of myocardial
infarction across different healthcare settings.
Methods
Study populations
This prospective observational study used three populations of
consecutive patients in the United Kingdom and the United
States. In an unselected patient population, we identified all
patients (n=1054) presenting to the emergency department at
the Royal Infirmary of Edinburgh, UK, in whom the attending
clinician did blood sampling irrespective of their clinical
presentation (fig 1⇓). In a second, independent, selected patient
population (n=5815), we identified all patients presenting to
secondary and tertiary care hospitals in the UK in whom the
attending clinician requested a cardiac troponin for suspected
acute coronary syndrome (fig 1⇓).17 18 In a third, selected patient
population (n=1631), we identified all patients in whom serial
cardiac troponin measurements were ordered by the attending
clinician for suspected acute coronary syndrome at the Hennepin
County Medical Center (Minneapolis, MN, USA).19 Patients in
the selected US population had to have a baseline cardiac
troponin measurement at presentation and at least one additional
measurement within 24 hours of presentation, before discharge.
Across all three populations, we excluded patients if they had
ST segment elevation myocardial infarction or a previous
presentation during the study period. We obtained baseline
clinical characteristics and investigations from a standardised
electronic patient record as previously described.2-19 We used
regional and national registries to follow up all patients for death
from any cause.20 This method allowed capture of all deaths in
hospital and in the community, ensuring complete follow-up.
All three patient populations included consecutive patients with
approval from the regional or national research ethics committee
and in accordance with the Declaration of Helsinki. To ensure
that every eligible patient was included and avoid selection bias,
consent was not sought from patients. All results and associated
data were anonymised and linked.
Cardiac troponin I assay
In all three populations, cardiac troponin testing was done at
the discretion of the attending physician by using a
contemporary cardiac troponin I assay (Abbott Laboratories,
Abbott Park, IL, USA). Plasma surplus to clinical requirements
was used to measure cardiac troponin I concentration with the
ARCHITECT
STAT
 high-sensitive troponin I assay (Abbott
Laboratories). In the unselected population, plasma was
available from the sample obtained at presentation only, whereas
in both selected populations high sensitivity cardiac troponin
was measured in parallel with the contemporary assay at
presentation and in all serial samples. The high sensitivity assay
has an inter-assay coefficient of variation less than 10% at 4.7
ng/L. The 99th centile upper reference limit is 34 ng/L in men
and 16 ng/L in women.18 21 Clinicians were blinded to the results
of the high sensitivity assay. Across all three populations, only
results from the contemporary assay, where requested by the
attending clinician, were used to guide patient care.
Classification of myocardial injury and
infarction
The diagnosis was adjudicated according to the universal
definition of myocardial infarction,22 using the high sensitivity
cardiac troponin I assay. Two physicians independently reviewed
all clinical information, including non-invasive and invasive
investigations and outcomes from presentation to 30 days.2-23
Any discrepancies were resolved by the adjudication of a third
independent reviewer. Type 1 myocardial infarction was defined
as myocardial necrosis in the context of a presentation with
suspected acute coronary syndrome with symptoms or signs of
myocardial ischaemia on the electrocardiogram (supplementary
table A). Patients with symptoms or signs of myocardial
ischaemia due to increased oxygen demand or decreased supply
(for example, tachyarrhythmia, hypotension, or anaemia)
secondary to an alternative pathology and myocardial necrosis
were classified as type 2 myocardial infarction. Myocardial
injury was defined as evidence of myocardial necrosis in the
absence of any clinical features of myocardial ischaemia
(supplementary table A).
Patient and public involvement
Both patients and lay representatives are members of the trial
steering committee for the High-STEACS clinical trial and all
related studies (NCT01852123) and were involved in the design
and conduct of this study. Lay summaries of the results,
alongside access to the published article, will be available from
the University of Edinburgh and the clinical trial website (https:
//highsteacs.com/).
Statistical analysis
We summarised baseline data for categorical variables as
proportions and presented continuous data as mean and standard
deviation or median and interquartile range as appropriate. Using
the unselected patient population, we calculated the prevalence
of the adjudicated diagnosis of type 1 myocardial infarction
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(reference standard) and the subsequent positive predictive
values for a range of pre-test probabilities, including that
observed in this population. We used the binomial exact method
to estimate confidence intervals for all proportions (see appendix
for full statistical analysis plan). We evaluated agreement for
the adjudication of diagnosis of type 1 myocardial infarction
versus other causes of myocardial injury by using the κ statistic.
Using the same method as in the unselected patient population,
we determined the observed positive predictive value and the
95% confidence interval of an elevated cardiac troponin for the
adjudicated diagnosis of type 1 myocardial infarction (reference
standard) in the two selected populations from the UK and US.
We determined the observed positive predictive value and
specificity across pre-specified groups stratified by age,
presenting symptoms, risk factors, presence of ischaemia on
electrocardiogram, and previous history of ischaemic heart
disease. This was a post hoc analysis of the previously published
selected UK and US populations,17-19 so no sample size
calculations were done for this analysis. The sample size of the
unselected patient population was based on the anticipated
prevalence of type 1 myocardial infarction. We determined that
we would need 1000 patients to estimate a prevalence of 2.5%
with an upper 95% confidence limit of less than 5% at greater
than 90% power with an α of 0.05. We used R version 3.2.3 for
all analyses.
Results
During recruitment of the unselected patient population, 3619
visits to the emergency department were made, from which
1130 patients underwent blood sampling for their presenting
complaint (fig 1⇓). Seventy six patients met our exclusion
criteria, giving a final study population of 1054 patients with a
mean age of 54 (SD 23) years (52.1% women) (table 1⇓).
Cardiac troponin was requested by the attending physician in
3.8% (136/3619) of all visits and in 12.9% (136/1054) of the
study population (supplementary table B). Of the patients for
whom the attending clinician requested cardiac troponin, 6%
(8/136; 7 female, 1 male) would have been reclassified using
the high sensitivity, with two diagnosed as having type 1
myocardial infarction (supplementary table C). Most of the
reclassified patients were women, reflecting the lower 99th
centile upper reference limit in women (supplementary table
C). More than half of all patients (609/1054; 57.8%) were
admitted, of whom 15.9% (97/609) had troponin requested by
the attending clinician (supplementary figure). Patients who
had cardiac troponin requested by the attending physician were
older and were more likely to be male, to have cardiovascular
risk factors, to present with chest pain, and to have intermediate
or high GRACE scores (supplementary table B).24 The frequency
of chest pain as the presenting complaint was 8.3% (75/906) in
patients in whom the attending clinician did not request cardiac
troponin.
In the selected population attending the emergency department
in the UK, the attending clinician requested cardiac troponin in
5815 consecutive patients (mean age 64 (16) years; 43.9%
female) (fig 1⇓ and table 1⇓). Patients selected for troponin
testing were more likely to present with chest pain and had a
higher prevalence of cardiovascular risk factors compared with
unselected patients.
In the selected population attending the emergency department
in the US, the attending clinician requested cardiac troponin in
1631 consecutive patients (mean age 57 (15) years; 44.1%
female) (fig 1⇓ and table 1⇓). Patients selected for troponin
testing in the US were less likely to present with chest pain
compared with those selected for testing in the UK (51.2% v
83.0%). Agreement between adjudicating physicians for the
diagnosis of type 1 myocardial infarction was good across both
the UK and US cohorts (κ=0.86 (95% confidence interval 0.83
to 0.89) and 0.75 (0.65 to 0.86), respectively). Death at 30 days
for all populations is reported in supplementary table D.
Prevalence of myocardial infarction and
positive predictive value of cardiac troponin
in unselected patients
In the unselected population attending the emergency department
in the UK, 13.7% (144/1054) had high sensitivity cardiac
troponin I concentrations above the 99th centile, with 17 (1.6%),
13 (1.2%), and 114 (10.8%) patients classified as having type
1 myocardial infarction, type 2 myocardial infarction, and
myocardial injury, respectively. Of all patients with cardiac
troponin concentrations above the 99th centile, chest pain
(36/144; 25%), falls or collapse (40/144; 28%), and dyspnoea
(13/144; 9%) were the most common presenting complaints
(supplementary table E). The most common diagnoses were
cardiac (35/144; 24%), respiratory (23/144; 16%), and infectious
diseases (21/144; 15%). Overall, the prevalence of type 1
myocardial infarction was 1.6% (17/1054), with a positive
predictive value for type 1 myocardial infarction of 11.8% (95%
confidence interval 7.0% to 18.2%) (fig 2⇓, fig 3⇓, and table
2⇓).
Prevalence of myocardial infarction and
positive predictive value of cardiac troponin
in selected patients (UK)
In the selected population undergoing troponin testing in the
UK, high sensitivity cardiac troponin was elevated in 24.1%
(95% confidence interval 23.0% to 25.2%) (1403/5815) of all
patients. Type 1 myocardial infarction adjudicated in 68 (4.2%)
patients, with 102 (6.3%) and 245 (15.0%) patients classified
as having type 2 myocardial infarction and myocardial injury,
respectively (table 1⇓). The prevalence of type 1 myocardial
infarction was 14.5% (843/5825) and the positive predictive
value was 59.7% (57.0% to 62.2%) (fig 2⇓, fig 3⇓, and table
2⇓). The positive predictive value was highest in patients with
chest pain (67.5%, 64.6% to 70.3%), evidence of myocardial
ischaemia on electrocardiography (69.9%, 65.8% to 73.7%), or
known ischaemic heart disease (68.1%, 64.1% to 72.0%)
compared with those without (34.0% (29.0% to 39.4%), 57.5%
(53.9% to 61.1%), and 55.1% (51.5% to 58.7%), respectively)
(fig 4⇓ and supplementary table F). The positive predictive
value was 83.2% (76.8% to 88.5%) in patients with all three of
these clinical features.
Prevalence of myocardial infarction and
positive predictive value of cardiac troponin
in selected patients (US)
In the selected population undergoing serial troponin testing in
the US, high sensitivity cardiac troponin was elevated in 25.4%
(23.3% to 27.6%) (415/1631), with type 1 myocardial infarction
adjudicated in 68 (4.2%) patients and 102 (6.3%) and 245
(15.0%), respectively, patients classified as having type 2
myocardial infarction and myocardial injury (table 1⇓). The
prevalence of type 1 myocardial infarction was 4.2% (68/1631)
and the positive predictive value was 16.4% (13.0% to 20.3%)
(fig 2⇓, fig 3⇓, and table 2⇓). Similar to the selected population
in the UK, the presence of chest pain, myocardial ischaemia on
electrocardiography, and history of ischaemic heart disease
improved the pre-test and post-test probability for a diagnosis
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of type 1 myocardial infarction (fig 4⇓ and supplementary table
G).
Discussion
We have evaluated the effect of selection of patients for high
sensitivity cardiac troponin testing on the diagnosis of
myocardial infarction in consecutive patients attending the
emergency department in the UK and US, and we make several
observations. Firstly, if testing is done in all patients without
selection, elevated cardiac troponin concentrations are frequent,
occurring in one in every eight patients. Most of these patients
are admitted to hospital with an alternative primary diagnosis
and are adjudicated as having type 2 myocardial infarction or
myocardial injury. Testing without patient selection results in
a very low prevalence of type 1 myocardial infarction (1.6%),
and the positive predictive value of an elevated cardiac troponin
concentration for type 1 myocardial infarction is low at 11.8%.
Secondly, patient selection for cardiac troponin testing varies
across healthcare settings and markedly influences the
prevalence and positive predictive value for a diagnosis of
myocardial infarction. In the UK, where the approach to testing
is more conservative, the prevalence of type 1 myocardial
infarction was 14.5% and the positive predictive value of high
sensitivity cardiac troponin testing was 59.7%. However, in the
US, where troponin testing is performed more widely, the
prevalence and positive predictive value for type 1 myocardial
infarction were much lower. Thirdly, across both healthcare
settings, testing in those patients with a higher pre-test
probability, such as those with chest pain, increases the positive
predictive value of high sensitivity cardiac troponin threefold.
These findings highlight the importance of the selection of
patients for testing if we are to optimise the diagnostic utility
of high sensitivity cardiac troponin.
Strengths of study
Our study has several strengths. Firstly, we minimised selection
bias by identifying all consecutive patients across all three study
populations. As such, we have evaluated the performance of
high sensitivity cardiac troponin testing as it is used in clinical
practice. Secondly, we did not rely on the contemporary cardiac
troponin assays for the diagnosis, but instead two cardiologists
independently adjudicated the diagnosis in all patients by using
the high sensitivity cardiac troponin I assay with sex specific
thresholds as the reference standard.47 Thirdly, we evaluated the
effect of patient selection on the prevalence and positive
predictive value of cardiac troponin for myocardial infarction
across two healthcare settings with different approaches to
testing.13 Together these approaches ensure that our observations
on the effect of patient selection for testing are generalisable
and relevant for clinical practice across different healthcare
settings.
Implications of findings
Our study has implications for the adoption of high sensitivity
cardiac troponin assays, particularly in those regions, such as
the US, where the frequency of testing is high.13 The positive
predictive value depends on the prevalence of type 1 myocardial
infarction, which in turn depends on the selection of patients
for testing, which differs widely across healthcare systems. In
a representative sample of more than 44 000 patients attending
more than 500 emergency departments in the US, 17% of all
patients and 47% of those admitted to hospital had cardiac
biomarkers tested,5 compared with just 3% and 16% respectively
in our selected population in the UK. Interestingly, in this
analysis, less than a third of patients tested in the US presented
with chest pain.5 We acknowledge that patients with suspected
acute coronary syndrome may present with atypical symptoms,48
but this proportion is unlikely to differ between healthcare
settings. We observed that chest pain was the presenting
symptoms in 83% of patients selected for testing in the UK,
compared with 51% in our US population. Differences in the
proportion of patients presenting with chest pain probably reflect
differences in the approach to clinical assessment before testing
and to other factors that influence the clinicians’ perception of
risk and therefore the need to exclude acute coronary syndrome.
The only other previous study of high sensitivity cardiac
troponin I testing in a US emergency department reported a
similar low prevalence of type 1 myocardial infarction of just
3.2%,49 which we estimate would give a positive predictive
value of 13.4% (fig 3⇓).
High sensitivity cardiac troponin assays are now being
introduced worldwide, with the exception of the US where they
have only recently been approved by the Food and Drug
Administration.50 Although cardiac troponin testing in
undifferentiated patients may be justified when myocardial
infarction is a possibility,51 52 it is important that clinicians are
aware that elevated cardiac troponin concentrations are not
exclusive to type 1 myocardial infarction. Implementation of
high sensitivity cardiac troponin testing should be accompanied
by education of clinicians to guide patient selection and the
interpretation of elevated troponin concentrations, and testing
should be incorporated into evidence based pathways. If
implemented without adoption of a considered approach, high
sensitivity cardiac troponin assays may increase diagnostic
uncertainty and increase the need for further invasive and
non-invasive cardiac investigations with cost implications for
the healthcare system.14
In the UK, where the approach to investigation is more
conservative, we observed that troponin testing was performed
in patients with a higher pre-test probability of myocardial
infarction, and the positive predictive value of high sensitivity
cardiac troponin was higher than in the US. Perhaps
unsurprisingly, the positive predictive value across both
populations was highest in patients with chest pain, myocardial
ischaemia on the electrocardiogram, or known ischaemic heart
disease, reflecting the higher prevalence of myocardial infarction
in patients with these features. Interestingly, the presence of
other established risk factors, such as hypertension and diabetes
mellitus, did not increase the positive predictive value for a
diagnosis of myocardial infarction in either population. Patients
with hypertension and diabetes mellitus are clearly at higher
risk of myocardial infarction and have a higher prevalence in
both populations, but they are also more likely to have
myocardial injury due to their comorbidities, which increases
the number of false positives and reduces specificity. Therefore,
the overall diagnostic performance of high sensitivity cardiac
troponin is influenced by both patient selection (prevalence)
and the presence of comorbid conditions (specificity), and
clinicians need to be aware of both when selecting patients for
testing and interpreting elevated cardiac troponin concentrations
in their practice.
What is the optimal positive predictive value for high sensitivity
cardiac troponin testing in this setting? Most studies report a
positive predictive value of between 45% and 65% (fig 3⇓), but
as yet no consensus exists on the optimal value. The ideal test
would identify only those patients with myocardial infarction,
but given that many causes of myocardial injury other than acute
coronary syndrome exist, even with careful clinical assessment
and selection of patients for testing, the positive predictive value
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is always going to be below 100%. In this context, a test that
identified more patients with the condition than without might
be acceptable. It is important that clinicians are aware of the
predictive value of testing and use the results to inform
subsequent investigations rather than starting treatment for
myocardial infarction in all patients with elevated cardiac
troponin concentrations.
Although a more selective approach to testing clearly improves
the positive predictive value, could this potentially lead to
clinicians missing patients with myocardial infarction? Among
the 1054 unselected patients, a total of 17 patients had type 1
myocardial infarction and 13 patients had type 2 myocardial
infarction. Of these 30 patients, five (two with type 1 myocardial
infarction and three with type 2 myocardial infarction) did not
have cardiac troponin requested by the attending clinician. Four
patients were managed appropriately for their primary presenting
condition without the need for troponin testing, and one patient
was discharged with atypical chest pain in whom testing would
have been informative (supplementary table H). Interestingly,
the approach to testing does not influence the negative predictive
value of our previously defined risk stratification threshold to
rule out myocardial infarction at presentation.17 Across both the
selected UK and US cohorts, the safety and efficacy of rule-out
strategies using high sensitivity troponin assays remained
comparable.17
Although elevated cardiac troponin concentrations without acute
coronary syndrome may be challenging to interpret, they convey
potentially important clinical information. Nearly all of these
patients were already recognised by their attending physician
as being acutely unwell and were admitted to hospital. Cardiac
troponin is a powerful prognostic marker in patients with type
2 myocardial infarction or myocardial injury,2 but no guidance
exists on how to investigate these patients, including the role
of cardiac monitoring, and as yet no evidence is available to
suggest that cardiovascular treatments will improve outcomes.2
Further studies are now needed to systematically evaluate
patients with type 2 myocardial infarction and myocardial injury,
to determine the underlying mechanisms, and to inform the
optimal management of these patients.
Limitations of study
Our study has some limitations that merit discussion. Firstly,
we did not do serial cardiac troponin testing or systematically
do coronary investigations in our population of unselected
patients. As a result, we may have underestimated the prevalence
of type 1 myocardial infarction and, despite our careful attempt
to classify patients, we accept that some patients may have been
misclassified. Reassuringly, the relation between prevalence of
myocardial infarction and positive predictive value was
consistent in our US population, where all patients had up to
four serial high sensitivity cardiac troponin tests, suggesting the
lack of serial testing in our unselected patients has not
compromised our analysis. In our practice, we advocate serial
testing in all patients with myocardial injury to clarify the
mechanism of injury and to document whether a rise and/or fall
in cardiac troponin has occurred to support the diagnosis of
myocardial infarction. Secondly, we acknowledge that although
most troponin tests in the emergency department are intended
to evaluate patients with suspected acute coronary syndrome,
guidelines recommend testing for cardiac biomarkers in other
acute presentations including pulmonary embolus and acute
heart failure.53 54 Although we have shown how high sensitivity
cardiac troponin testing without consideration of pre-test
probability affects the positive predictive value for type 1
myocardial infarction, we accept that cardiac troponin testing
is not used exclusively to evaluate patients with suspected acute
coronary syndrome. Thirdly, cardiac troponin is integral to the
diagnosis of myocardial infarction, and the absence of an
independent reference standard is a limitation of all diagnostic
studies evaluating high sensitivity cardiac troponin testing.18 55
However, this limitation does not affect the validity of our study
of the prevalence and effect of patient selection on the positive
predictive value of an elevated cardiac troponin concentration.
Conclusions
When high sensitivity cardiac troponin testing is performed
widely or without previous clinical assessment, elevated troponin
concentrations are common and predominantly reflect
myocardial injury rather than type 1 myocardial infarction. Our
observations highlight how selection of patients for cardiac
troponin testing varies across healthcare settings and markedly
influences the positive predictive value for a diagnosis of
myocardial infarction.
Contributors: ASVS and NLM designed the study and carried out the
initial acquisition, analysis, or interpretation of data. All authors were
involved in drafting and revising the manuscript and have given final
approval of the version to be published. ASVS is the guarantor.
Funding: This research was funded by the British Heart Foundation
(SP/12/10/29922 and PG/15/51/31596). NLM and DEN are supported
by the Butler Senior Clinical Research Fellowship (FS/16/14/32023)
and John Wheatley Chair (CH/09/002) awards respectively from the
British Heart Foundation. DAM is supported by the Wellcome Trust
(Intermediate Clinical Fellowship 201492/Z/16/Z). Abbott Laboratories
provided high sensitivity cardiac troponin I assay reagents, calibrators,
and controls.
Competing interests: All authors have completed the ICMJE uniform
disclosure form at www.icmje.org/coi_disclosure.pdf (available on
request from the corresponding author) and declare: support for the
submitted work as described above; NLM has acted as a consultant for
Abbott Diagnostics, Roche Diagnostics, and Singulex; ASVS has acted
as a consultant for Abbott Diagnostics; AC has received speaker fees
from Abbott Diagnostics; FSA has acted as a consultant to Metanomics
Healthcare, an advisor to Instrumentation Laboratory and Abbott
Diagnostics, and on the Board of Directors of HyTest Ltd; YS has acted
as an advisor for Roche Diagnostics; no other relationships or activities
that could appear to have influenced the submitted work.
Ethical approval: All three patient populations in this study included
consecutive patients with approval from the regional or national research
ethics committee and in accordance with the Declaration of Helsinki.
For the unselected patient population, approval to obtain plasma surplus
to clinical requirement was granted by the National Research Scotland
BioResource and Tissue Governance Unit. For the selected patient
populations in the UK and US, approval was granted by the Scotland
A Regional Ethics Committee and the Human Subjects Research
Committee of Hennepin County Medical Center respectively.
Data sharing: Patient level data and statistical code will be available
from the corresponding author following publication of the primary study
(HighSTEACS: NCT01852123). Participants’ consent to share data was
not obtained, but the presented data are anonymised and risk of
identification is low.
Transparency declaration: The lead author (the manuscript’s guarantor)
affirms that the manuscript is an honest, accurate, and transparent
account of the study being reported; that no important aspects of the
study have been omitted; and that any discrepancies from the study as
planned (and, if relevant, registered) have been explained.
1 Shah AS, Newby DE, Mills NL. High sensitivity cardiac troponin in patients with chest
pain. BMJ 2013;359:f4222. doi:10.1136/bmj.f4222 pmid:23878152.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2017;359:j4788 doi: 10.1136/bmj.j4788 (Published 2017 November 07) Page 5 of 12
RESEARCH
What is already known on this topic
High sensitivity cardiac troponin assays may improve the diagnosis of myocardial infarction but increase the detection of myocardial
injury in patients without acute coronary syndrome
Lower diagnostic thresholds disproportionately increase the number of patients with troponin elevations who do not have acute coronary
syndrome
What this study adds
High sensitivity cardiac troponin testing in all patients results in elevated troponin concentrations in one in eight patients, most of whom
do not have type 1 myocardial infarction
Patient selection for cardiac troponin testing varies across healthcare settings in the UK and US, markedly influencing the prevalence
and positive predictive value for a diagnosis of myocardial infarction
Selection of patients with a higher pre-test probability based on simple clinical features improved the positive predictive value
2 Shah AS, McAllister DA, Mills R, et al. Sensitive troponin assay and the classification of
myocardial infarction. Am J Med 2015;359:493-501.e3. doi:10.1016/j.amjmed.2014.10.
056 pmid:25436428.
3 Newby LK, Jesse RL, Babb JD, et al. ACCF 2012 expert consensus document on practical
clinical considerations in the interpretation of troponin elevations: a report of the American
College of Cardiology Foundation task force on Clinical Expert Consensus Documents.
J Am Coll Cardiol 2012;359:2427-63. doi:10.1016/j.jacc.2012.08.969 pmid:23154053.
4 Saaby L, Poulsen TS, Hosbond S, et al. Classification of myocardial infarction: frequency
and features of type 2 myocardial infarction. Am J Med 2013;359:789-97. doi:10.1016/j.
amjmed.2013.02.029 pmid:23856021.
5 Saaby L, Poulsen TS, Diederichsen AC, et al. Mortality rate in type 2 myocardial infarction:
observations from an unselected hospital cohort. Am J Med 2014;359:295-302. doi:10.
1016/j.amjmed.2013.12.020 pmid:24457000.
6 Sandoval Y, Thygesen K. Myocardial Infarction Type 2 and Myocardial Injury. Clin Chem
2017;359:101-7. doi:10.1373/clinchem.2016.255521 pmid:28062614.
7 Sandoval Y, Smith SW, Thordsen SE, Apple FS. Supply/demand type 2 myocardial
infarction: should we be paying more attention?J Am Coll Cardiol 2014;359:2079-87. doi:
10.1016/j.jacc.2014.02.541 pmid:24632278.
8 Morrow DA, Wiviott SD, White HD, et al. Effect of the novel thienopyridine prasugrel
compared with clopidogrel on spontaneous and procedural myocardial infarction in the
Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition
with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification
system from the universal definition of myocardial infarction. Circulation 2009;359:2758-64.
doi:10.1161/CIRCULATIONAHA.108.833665 pmid:19451347.
9 Melberg T, Burman R, Dickstein K. The impact of the 2007 ESC-ACC-AHA-WHF Universal
definition on the incidence and classification of acute myocardial infarction: a retrospective
cohort study. Int J Cardiol 2010;359:228-33. doi:10.1016/j.ijcard.2008.10.021 pmid:
19027971.
10 Stein GY, Herscovici G, Korenfeld R, et al. Type-II myocardial infarction--patient
characteristics, management and outcomes. PLoS One 2014;359:e84285. doi:10.1371/
journal.pone.0084285 pmid:24392121.
11 Mills NL, Churchhouse AM, Lee KK, et al. Implementation of a sensitive troponin I assay
and risk of recurrent myocardial infarction and death in patients with suspected acute
coronary syndrome. JAMA 2011;359:1210-6. doi:10.1001/jama.2011.338 pmid:21427373.
12 Melanson SE, Conrad MJ, Mosammaparast N, Jarolim P. Implementation of a highly
sensitive cardiac troponin I assay: test volumes, positivity rates and interpretation of
results. Clin Chim Acta 2008;359:57-61. doi:10.1016/j.cca.2008.05.007 pmid:18515084.
13 Makam AN, Nguyen OK. Use of cardiac biomarker testing in the emergency department.
JAMA Intern Med 2015;359:67-75. doi:10.1001/jamainternmed.2014.5830 pmid:25401720.
14 Eggers KM, Lindahl B, Melki D, Jernberg T. Consequences of implementing a cardiac
troponin assay with improved sensitivity at Swedish coronary care units: an analysis from
the SWEDEHEART registry. Eur Heart J 2016;359:2417-24. doi:10.1093/eurheartj/
ehw029 pmid:26916797.
15 Yiadom MY, Jarolim P, Jenkins C, Melanson SE, Conrad M, Kosowsky JM. Diagnostic
implications of an elevated troponin in the emergency department. Dis Markers
2015;359:157812. doi:10.1155/2015/157812 pmid:25960590.
16 Baxi S, Lakin J, Stapleton S, Redberg R. High-sensitivity troponin: elevated without
infarction, is the horse out of the barn?Emerg Med J 2014;359:354-5. doi:10.1136/
emermed-2013-202796 pmid:23825057.
17 Shah AS, Anand A, Sandoval Y, et al. High-STEACS investigators. High-sensitivity cardiac
troponin I at presentation in patients with suspected acute coronary syndrome: a cohort
study. Lancet 2015;359:2481-8. doi:10.1016/S0140-6736(15)00391-8 pmid:26454362.
18 Shah AS, Griffiths M, Lee KK, et al. High sensitivity cardiac troponin and the
under-diagnosis of myocardial infarction in women: prospective cohort study. BMJ
2015;359:g7873. doi:10.1136/bmj.g7873 pmid:25609052.
19 Sandoval Y, Smith SW, Shah AS, et al. Rapid Rule-Out of Acute Myocardial Injury Using
a Single High-Sensitivity Cardiac Troponin I Measurement. Clin Chem 2017;359:369-76.
doi:10.1373/clinchem.2016.264523 pmid:27811203.
20 Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM. West of Scotland
Coronary Prevention Study Group. Long-term follow-up of the West of Scotland Coronary
Prevention Study. N Engl J Med 2007;359:1477-86. doi:10.1056/NEJMoa065994 pmid:
17928595.
21 Shah ASV, Ferry AV, Mills NL. Cardiac Biomarkers and the Diagnosis of Myocardial
Infarction in Women. Curr Cardiol Rep 2017;359:40. doi:10.1007/s11886-017-0839-9 pmid:
28391559.
22 Thygesen K, Alpert JS, Jaffe AS, et al. Joint ESC/ACCF/AHA/WHF Task Force for the
Universal Definition of Myocardial Infarction. Third universal definition of myocardial
infarction. Circulation 2012;359:2020-35. doi:10.1161/CIR.0b013e31826e1058 pmid:
22923432.
23 Sandoval Y, Smith SW, Love SA, Sexter A, Schulz K, Apple FS. Single High-Sensitivity
Cardiac Troponin I to Rule Out Acute Myocardial Infarction. Am J Med
2017;359:1076-1083.e1. doi:10.1016/j.amjmed.2017.02.032 pmid:28344141.
24 Fox KA, Dabbous OH, Goldberg RJ, et al. Prediction of risk of death and myocardial
infarction in the six months after presentation with acute coronary syndrome: prospective
multinational observational study (GRACE). BMJ 2006;359:1091. doi:10.1136/bmj.38985.
646481.55 pmid:17032691.
25 Invernizzi L, Doka M, Cappellini F, et al. Effectiveness of highly sensitive troponin T assay
for early diagnosis of acute myocardial infarction (AMI). Biochim Clin 2013;359:36-9.
26 Lotze U, Lemm H, Heyer A, Müller K. Combined determination of highly sensitive troponin
T and copeptin for early exclusion of acute myocardial infarction: first experience in an
emergency department of a general hospital. Vasc Health Risk Manag 2011;359:509-15.
doi:10.2147/VHRM.S21753 pmid:21915168.
27 Bahrmann P, Bahrmann A, Breithardt OA, et al. Additional diagnostic and prognostic
value of copeptin ultra-sensitive for diagnosis of non-ST-elevation myocardial infarction
in older patients presenting to the emergency department. Clin Chem Lab Med
2013;359:1307-19. doi:10.1515/cclm-2012-0401 pmid:23314553.
28 Bahrmann P, Christ M, Bahrmann A, et al. A 3-hour diagnostic algorithm for
non-ST-elevation myocardial infarction using high-sensitivity cardiac troponin T in
unselected older patients presenting to the emergency department. J Am Med Dir Assoc
2013;359:409-16. doi:10.1016/j.jamda.2012.12.005 pmid:23375478.
29 Hammerer-Lercher A, Ploner T, Neururer S, et al. High-sensitivity cardiac troponin T
compared with standard troponin T testing on emergency department admission: how
much does it add in everyday clinical practice?J Am Heart Assoc 2013;359:e000204. doi:
10.1161/JAHA.113.000204 pmid:23735897.
30 Thelin J, Borna C, Erlinge D, Öhlin B. The combination of high sensitivity troponin T and
copeptin facilitates early rule-out of ACS: a prospective observational study. BMC
Cardiovasc Disord 2013;359:42. doi:10.1186/1471-2261-13-42 pmid:23777442.
31 Freund Y, Chenevier-Gobeaux C, Bonnet P, et al. High-sensitivity versus conventional
troponin in the emergency department for the diagnosis of acute myocardial infarction.
Crit Care 2011;359:R147. doi:10.1186/cc10270 pmid:21663627.
32 Santaló M, Martin A, Velilla J, et al. Using high-sensitivity troponin T: the importance of
the proper gold standard. Am J Med 2013;359:709-17. doi:10.1016/j.amjmed.2013.03.
003 pmid:23764266.
33 Hoeller R, Rubini Giménez M, Reichlin T, et al. Normal presenting levels of high-sensitivity
troponin and myocardial infarction. Heart 2013;359:1567-72. doi:10.1136/heartjnl-2013-
303643 pmid:23604180.
34 Body R, Carley S, McDowell G, et al. Rapid exclusion of acute myocardial infarction in
patients with undetectable troponin using a high-sensitivity assay. J Am Coll Cardiol
2011;359:1332-9. doi:10.1016/j.jacc.2011.06.026 pmid:21920261.
35 Aldous SJ, Florkowski CM, Crozier IG, Than MP. The performance of high sensitivity
troponin for the diagnosis of acute myocardial infarction is underestimated. Clin Chem
Lab Med 2011;359:727-9.pmid:22505533.
36 Aldous SJ, Richards AM, Cullen L, Than MP. Early dynamic change in high-sensitivity
cardiac troponin T in the investigation of acute myocardial infarction. Clin Chem
2011;359:1154-60. doi:10.1373/clinchem.2010.161166 pmid:21784766.
37 Christ M, Popp S, Pohlmann H, et al. Implementation of high sensitivity cardiac troponin
T measurement in the emergency department. Am J Med 2010;359:1134-42. doi:10.1016/
j.amjmed.2010.07.015 pmid:20932502.
38 Giannitsis E, Kehayova T, Vafaie M, Katus HA. Combined testing of high-sensitivity
troponin T and copeptin on presentation at prespecified cutoffs improves rapid rule-out
of non-ST-segment elevation myocardial infarction. Clin Chem 2011;359:1452-5. doi:10.
1373/clinchem.2010.161265 pmid:21807867.
39 Collinson P, Goodacre S, Gaze D, Gray A. RATPAC Research Team. Very early diagnosis
of chest pain by point-of-care testing: comparison of the diagnostic efficiency of a panel
of cardiac biomarkers compared with troponin measurement alone in the RATPAC trial.
Heart 2012;359:312-8. doi:10.1136/heartjnl-2011-300723 pmid:22076016.
40 Sebbane M, Lefebvre S, Kuster N, et al. Early rule out of acute myocardial infarction in
ED patients: value of combined high-sensitivity cardiac troponin T and ultrasensitive
copeptin assays at admission. Am J Emerg Med 2013;359:1302-8. doi:10.1016/j.ajem.
2013.04.033 pmid:23816196.
41 Inoue K, Suwa S, Ohta H, et al. Heart fatty acid-binding protein offers similar diagnostic
performance to high-sensitivity troponin T in emergency room patients presenting with
chest pain. Circ J 2011;359:2813-20. doi:10.1253/circj.CJ-11-0598 pmid:21937835.
42 Eggers KM, Venge P, Lindahl B. High-sensitive cardiac troponin T outperforms novel
diagnostic biomarkers in patients with acute chest pain. Clin Chim Acta 2012;359:1135-40.
doi:10.1016/j.cca.2012.03.011 pmid:22456003.
43 Normann J, Mueller M, Biener M, Vafaie M, Katus HA, Giannitsis E. Effect of older age
on diagnostic and prognostic performance of high-sensitivity troponin T in patients
presenting to an emergency department. Am Heart J 2012;359:698-705.e4. doi:10.1016/
j.ahj.2012.08.003 pmid:23137500.
44 Khan DA, Sharif MS, Khan FA. Diagnostic performance of high-sensitivity troponin T,
myeloperoxidase, and pregnancy-associated plasma protein A assays for triage of patients
with acute myocardial infarction. Korean J Lab Med 2011;359:172-8. doi:10.3343/kjlm.
2011.31.3.172 pmid:21779191.
45 Keller T, Zeller T, Ojeda F, et al. Serial changes in highly sensitive troponin I assay and
early diagnosis of myocardial infarction. JAMA 2011;359:2684-93. doi:10.1001/jama.2011.
1896 pmid:22203537.
46 Zhelev Z, Hyde C, Youngman E, et al. Diagnostic accuracy of single baseline measurement
of Elecsys Troponin T high-sensitive assay for diagnosis of acute myocardial infarction
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2017;359:j4788 doi: 10.1136/bmj.j4788 (Published 2017 November 07) Page 6 of 12
RESEARCH
in emergency department: systematic review and meta-analysis. BMJ 2015;359:h15. doi:
10.1136/bmj.h15 pmid:25646632.
47 Apple FS. A new season for cardiac troponin assays: it’s time to keep a scorecard. Clin
Chem 2009;359:1303-6. doi:10.1373/clinchem.2009.128363 pmid:19478023.
48 Canto JG, Shlipak MG, Rogers WJ, et al. Prevalence, clinical characteristics, and mortality
among patients with myocardial infarction presenting without chest pain. JAMA
2000;359:3223-9. doi:10.1001/jama.283.24.3223 pmid:10866870.
49 Korley FK, Schulman SP, Sokoll LJ, et al. Troponin elevations only detected with a
high-sensitivity assay: clinical correlations and prognostic significance. Acad Emerg Med
2014;359:727-35. doi:10.1111/acem.12417 pmid:25112512.
50 United States Food and Drug Administration. 510(k) substantial equivalence determination
decision summary assay only template. 2017. https://www.accessdata.fda.gov/cdrh_docs/
reviews/K162895.pdf.
51 Jairam S, Jones P, Samaraie L, Chataline A, Davidson J, Stewart R. Clinical diagnosis
and outcomes for Troponin T ‘positive’ patients assessed by a high sensitivity compared
with a 4th generation assay. Emerg Med Australas 2011;359:490-501. doi:10.1111/j.1742-
6723.2011.01446.x pmid:21824317.
52 Sherwood MW, Kristin Newby L. High-sensitivity troponin assays: evidence, indications,
and reasonable use. J Am Heart Assoc 2014;359:e000403. doi:10.1161/JAHA.113.
000403 pmid:24470520.
53 Konstantinides SV, Torbicki A, Agnelli G, et al. Task Force for the Diagnosis and
Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC).
2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism.
Eur Heart J 2014;359:3033-69, 3069a-3069k. doi:10.1093/eurheartj/ehu283 pmid:
25173341.
54 Ponikowski P, Voors AA, Anker SD, et al. Authors/Task Force Members Document
Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic
heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart
failure of the European Society of Cardiology (ESC). Developed with the special
contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail
2016;359:891-975. doi:10.1002/ejhf.592 pmid:27207191.
55 Glasziou P, Irwig L, Deeks JJ. When should a new test become the current reference
standard?Ann Intern Med 2008;359:816-22. doi:10.7326/0003-4819-149-11-200812020-
00009 pmid:19047029.
Accepted: 11 10 2017
Published by the BMJ Publishing Group Limited. For permission to use (where not already
granted under a licence) please go to http://group.bmj.com/group/rights-licensing/
permissions
This is an Open Access article distributed in accordance with the Creative Commons
Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute,
remix, adapt, build upon this work non-commercially, and license their derivative works
on different terms, provided the original work is properly cited and the use is
non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2017;359:j4788 doi: 10.1136/bmj.j4788 (Published 2017 November 07) Page 7 of 12
RESEARCH
Tables
Table 1| Baseline characteristics of unselected patients and patients selected for cardiac troponin testing in UK and US. Values are numbers
(percentages) unless stated otherwise
Selected patients (US) (n=1631)Selected patients (UK) (n=5815)Unselected patients (n=1054)Characteristics
720/1631 (44.1)2552 (43.9)549/1054 (52.0)Female sex
57 (15)64 (16)54 (23)Mean (SD) age, years
835/1572 (51.2)4825/5813 (83.0)183/1042 (17.6)Chest pain
Risk factors
592/1631 (36.3)1105/3615 (30.6)299/902 (33.1)Smoker
1074/1631 (65.9)1969/5233 (37.6)337/1041 (32.4)Hypertension
696/1631 (42.7)1611/5232 (30.8)299/1041 (28.7)Hyperlipidaemia
Past medical history
337/1631 (20.7)1846/5240 (35.2)193/1042 (18.5)Ischaemic heart disease
190/1629 (11.7)1082/5235 (20.7)109/1041 (10.5)Myocardial infarction
153/1631 (9.4)475/5340 (9.1)99/1041 (9.5)Cerebrovascular disease
505/1631 (31.0)842/5233 (16.1)106/1047 (10.1)Diabetes mellitus
150/1621 (9.2)611/5233 (11.7)52/1046 (5.0)PCI
73/1620 (4.5)330/5228 (6.3)32/1046 (3.1)CABG
Drugs at presentation
627 (38.4)1344 (33.7)180 (17.5)Aspirin
76 (4.7)468 (11.8)81 (7.9)Clopidogrel
589 (36.1)1082 (27.2)149 (14.5)β blockers
578 (35.4)1311 (32.9)189 (18.3)ACE-I/ARB
556 (34.1)1578 (39.6)249 (24.2)Statin
115 (7.1)278 (7.0)44 (4.3)Warfarin
Haemodynamics
143.7 (28.5)137.5 (26.0)130.5 (22.2)Mean (SD) systolic blood pressure, mm
Hg
90.2 (34.3)81.2 (22.9)86.9 (22.3)Mean (SD) heart rate, beats/min
Killip class
-4847/5336 (90.8)930/1037 (89.7)I
-408/5336 (7.6)85/1037 (8.2)II
-75/5336 (1.4)15/1037 (1.4)III
-6/5336 (0.1)1/1037 (0.1)IV
Baseline electrocardiography
304/1631 (18.6)218/5157 (4.2)13/656 (2.0)ST elevation*
212/1631 (13.0)397/5156 (7.7)21/653 (3.2)ST depression
316/1631 (19.4)726/5154 (14.1)58/653 (8.9)T wave inversion
Diagnosis
68/1631 (4.2)843/5815 (14.5)17/1054 (1.6)Type 1 myocardial infarction
102/1631 (6.3)229/5815 (3.9)13/1054 (1.2)Type 2 myocardial infarction
245/1631 (15.0)341/5815 (5.9)114/1054 (10.8)Myocardial injury
ACE-I/ARB=angiotensin converting enzyme inhibitor/angiotensin receptor blocker; CABG=coronary artery bypass grafting; PCI=percutaneous coronary intervention.
*In the selected US population, ST segment elevation was defined as an increase >0.5 mm in any lead.
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Table 2| Diagnosis of type 1 myocardial infarction using high sensitivity cardiac troponin
Diagnostic parameter, % (95% CI)
Total
Type 1 myocardial infarction
Positive predictive
value
Negative predictive
valueSpecificitySensitivityNoYes
Unselected cohort (n=1054)
11.8 (7.0 to 18.2)100 (99.6 to 100)87.7 (85.6 to 90.0) 100 (80.5 to 100)
---
High sensitivity cardiac troponin
>99th centile:
14412717  Yes
9109100  No
1054103717Total
Selected cohort, UK (n=5815)
59.7 (57.0 to 62.2)100 (99.9 to 100)88.5 (87.6 to 89.4)100 (99.6 to 100)
---
High sensitivity cardiac troponin
>99th centile:
1413570843  Yes
440244020  No
58154972843Total
Selected cohort, US (n=1631)
16.4 (13.0 to 20.3)100 (99.7 to 100)77.8 (75.7 to 79.8)100 (94.7 to 100)
---
High sensitivity cardiac troponin
>99th centile:
41534768  Yes
121612160  No
1631156368Total
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Figures
Fig 1 Flow diagram summarising enrolment of unselected patients and those selected for cardiac troponin testing in the
UK and US. ED=emergency department; STEMI=ST segment elevation myocardial infarction. *Troponin used only to guide
clinical care in patients with suspected acute coronary syndrome
Fig 2 Prevalence of elevated high sensitivity cardiac troponin concentrations and type 1 myocardial infarction in unselected
patients and those selected for cardiac troponin testing in the UK and US
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Fig 3 Influence of prevalence on positive predictive value of elevated high sensitivity cardiac troponin concentration for
diagnosis of type 1 myocardial infarction. Red dots represent populations of unselected patients in the emergency department
(n=1054) and selected patients in the UK (n=5815) and US (n=1631). Blue dots represent reported positive predictive
values for high sensitivity cardiac troponin by prevalence of type 1 myocardial infarction in previously published cohorts
using high sensitivity cardiac troponin T (blue) and high sensitivity cardiac troponin I (red) assays.25-45 Data for positive
predictive values for high sensitivity troponin T cohorts were extracted from a recent systematic review and meta-analysis
published by Zhelev et al.46 Dot size reflects number of patients in each cohort (small dot <500 patients, medium dot
500-1500 patients, large dot >1500 patients). Blue line represents central estimate of positive predictive value with 95%
confidence interval (dashed red lines) derived from unselected emergency department population in the UK
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Fig 4 Influence of clinical characteristics on positive predictive value of elevated high sensitivity cardiac troponin for diagnosis
of type 1 myocardial infarction in patients selected for troponin testing in the UK (top panel) and US (bottom panel). Solid
line represents positive predictive value across whole population, with dashed lines representing 95% confidence intervals
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